Profile
Assistant to the President, Chief Physician of Internal Medicine, Master of Medical Science, Standing Committee Member of the Foshan Cardiovascular Branch of the Chinese Medical Association, and Master's Graduate of Sun Yat-sen University of Medical Sciences. Proficient in the diagnosis and management of various cardiovascular diseases including hypertension, coronary heart disease, arrhythmias, congenital heart disease, and cardiomyopathy, with extensive clinical experience in the diagnosis and treatment of geriatric cardiovascular conditions. Has conducted in-depth research on echocardiography and cardiography, and has obtained research funding from the Provincial Health Department.
Speciality
· Diagnosis and management of hypertension, coronary heart disease, and arrhythmias.
· Extensive clinical experience in the diagnosis and treatment of geriatric cardiovascular diseases.
Professor Wang Qiang delivering a speech.
On July 31, 2024, the Foshan Fosun Chancheng Hospital Precision Tumor Diagnosis and Treatment Center successfully issued the first prescription in mainland China (excluding Hong Kong, Macao, and Taiwan) for the third-generation tyrosine kinase inhibitor (TKI) Ponatinib (trade name Iclusig®) under the "Greater Bay Area Drug and Medical Device Access" policy. This signifies that domestic leukemia patients now officially have access to genuine, guaranteed third-generation TKI targeted therapy, bringing new hope to their anti-cancer journey.
President Wang Qiang of Foshan Fosun Chancheng Hospital congratulating the successful introduction of Ponatinib to the hospital.
